Please use this identifier to cite or link to this item:
Title: CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype
Authors: Filippi, Silvia
Paccosi, Elena
Balzerano, Alessio
Ferretti, Margherita
Poli, Giulia
Taborri, Juri 
Brancorsini, Stefano
Proietti-De-Santis, Luca
Journal: CANCERS 
Issue Date: 2022
Breast cancer (BC) is the most common cancer with the highest frequency of death among women. BC is highly heterogenic at the genetic, biological, and clinical level. Despite the significant improvements in diagnosis and treatments of BC, the high rate of cancer recurrence and resistance to treatment remains a major challenge in clinical practice. This issue is particularly relevant in Triple-Negative Breast Cancer (TNBC) subtype, for which chemotherapy remains the main standard therapeutic approach. Here, we observed that BC cells, belonging to different subtypes, including the TNBC, display an increased expression of Cockayne Syndrome group A (CSA) protein, which is involved in multiple functions such as DNA repair, transcription, mitochondrial homeostasis, and cell division and that recently was found to confer cell robustness when it is up-regulated. We demonstrated that CSA ablation by AntiSense Oligonucleotides (ASOs) drastically impairs tumorigenicity of BC cells by hampering their survival and proliferative capabilities without damaging normal cells. Moreover, suppression of CSA dramatically sensitizes BC cells to platinum and taxane derivatives, which are commonly used for BC first-line therapy, even at very low doses not harmful to normal cells. Finally, CSA ablation restores drug sensitivity in oxaliplatin-resistant cells. Based on these results, we conclude that CSA might be a very attractive target for the development of more effective anticancer therapies.
ISSN: 2072-6694
DOI: 10.3390/cancers14071687
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Appears in Collections:A1. Articolo in rivista

Files in This Item:
File Description SizeFormat Existing users please
cancers-14-01687-v2.pdf1.98 MBAdobe PDF    Request a copy
Show full item record


Last Week
Last month
checked on Jan 26, 2023

Page view(s)

Last Week
Last month
checked on Jan 31, 2023

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons